RxDoctor Payments DataLook up a doctor →

Paul Forfia, MD

Cardiovascular Disease · Philadelphia, PANPI 1245316058

Payments from drug & device makers

$1,219,595in general payments, 2019–2025

Across 1,160 payments — averaging $1051.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$430K
  • Actelion Pharmaceuticals US, Inc.$363K
  • Bayer$305K
  • Merck$78K
  • Actelion Pharmaceuticals, Ltd$25K
  • Janssen Research & Development, LLC$17K
  • plus $385 from 5 others
$21,875in research payments, 2019–2025

Across 1 payment — averaging $21,875 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Actelion Pharmaceuticals US, Inc.$22K

What the payments were for

  • Consulting fees$181,55915%
  • Speaking & faculty fees$867,19273%
  • Travel & lodging$118,77510%
  • Food & beverage$24,0382%
  • Education$820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,219,595 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$55,343
Medicare patients
149
Services billed
546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat300$4,141,816
Tyvaso DpiTreprostinil104$2,485,738
OpsumitMacitentan179$2,259,701
Orenitram ErTreprostinil Diolamine48$605,989
WinrevairSotatercept-Csrk19$272,183
LetairisAmbrisentan14$181,669
UptraviSelexipag12$176,730
Ambrisentan73$148,786
TracleerBosentan11$137,267
Bosentan26$69,540
Sildenafil Citrate152$46,628
EliquisApixaban46$43,333
Tadalafil58$33,470
XareltoRivaroxaban16$12,756
FarxigaDapagliflozin Propanediol12$9,718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$305,016$4,141,816300 claims
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Tracleer, Bosentan$362,826$2,643,238228 claims
MerckWinrevair$78,328$272,18319 claims
GileadLetairis$137$181,66914 claims
Johnson & JohnsonXarelto$16$12,75616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →